Trillium Asset Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 26.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,784 shares of the biopharmaceutical company’s stock after purchasing an additional 13,300 shares during the quarter. Trillium Asset Management LLC’s holdings in Gilead Sciences were worth $4,444,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Waldron LP grew its stake in Gilead Sciences by 20.4% during the 1st quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock valued at $711,000 after purchasing an additional 1,752 shares in the last quarter. Whittier Trust Co. lifted its holdings in Gilead Sciences by 5.0% during the 1st quarter. Whittier Trust Co. now owns 164,813 shares of the biopharmaceutical company’s stock worth $11,194,000 after buying an additional 7,801 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in Gilead Sciences by 6.9% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 100,339 shares of the biopharmaceutical company’s stock worth $6,815,000 after buying an additional 6,489 shares during the last quarter. Hennessy Advisors Inc. lifted its holdings in Gilead Sciences by 49.9% during the 1st quarter. Hennessy Advisors Inc. now owns 31,400 shares of the biopharmaceutical company’s stock worth $2,133,000 after buying an additional 10,457 shares during the last quarter. Finally, Wesbanco Bank Inc. lifted its holdings in Gilead Sciences by 2.5% during the 1st quarter. Wesbanco Bank Inc. now owns 28,529 shares of the biopharmaceutical company’s stock worth $1,938,000 after buying an additional 697 shares during the last quarter. Hedge funds and other institutional investors own 73.97% of the company’s stock.

In related news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total value of $6,054,372.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP James R. Meyers sold 60,000 shares of the company’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total transaction of $4,991,400.00. Following the completion of the sale, the executive vice president now owns 62,715 shares of the company’s stock, valued at approximately $5,217,260.85. The disclosure for this sale can be found here. In the last three months, insiders sold 486,819 shares of company stock worth $39,298,919. 1.30% of the stock is currently owned by company insiders.

A number of research analysts have commented on the company. Jefferies Group LLC reaffirmed a “hold” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Tuesday, July 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a report on Thursday, July 13th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $82.00 target price on shares of Gilead Sciences in a report on Tuesday, July 4th. Finally, BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Twelve equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $85.80.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 81.17 on Monday. The firm has a market capitalization of $106.00 billion, a PE ratio of 8.82 and a beta of 1.14. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company has a 50 day moving average price of $82.48 and a 200-day moving average price of $72.25.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.08 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Holdings Raised by Trillium Asset Management LLC” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-holdings-raised-by-trillium-asset-management-llc/1633630.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.